Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts,...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced an article about long-term health outcomes of its investigational...
Geisinger and Eisai Inc. today announced a collaborative effort to study the potential effectiveness of an artificial intelligence (AI) tool in the...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the company will present research from its robust neurology...
Actor, director and activist Meagan Good has partnered with FORCE, SHARE, Black Health Matters and Eisai Inc. on the Spot Her® campaign to help raise ...
Sysmex Corporation (Chairman and CEO: Hisashi Ietsugu; hereafter, "Sysmex") and Eisai Co., Ltd. (CEO: Haruo Naito; hereafter, "Eisai") are aiming to...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present research from its robust Alzheimer's...
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the expansion of its leadership team to include Tricia Brooks as...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the Dominantly Inherited Alzheimer Network Trials Unit...
Eisai announced today the presentation of six abstracts across various gastrointestinal cancers during the 2022 American Society of Clinical Oncology ...
Eisai Inc. presented data from PERMIT, a large real-world clinical study evaluating its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII,...
Eisai Inc. and METAvivor today announced the launch of fearLESS, a new initiative of the #ThisIsMBC campaign. FearLESS showcases content of a diverse ...
Eisai Inc. presented analyses of the ELEVATE study of its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2021 American Epilepsy Society...
Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 75th American Epilepsy Society ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of data from the company's extensive Alzheimer's...
Eisai Inc. announced today the presentation of 13 abstracts across multiple types of cancer from its oncology portfolio during the upcoming European...
Eisai today announced that H3 Biomedicine (H3), its cancer genomics-based drug discovery subsidiary company located in Cambridge, Mass., has...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.